Please sign in to follow a disease.
Which cough syrup works best? new study puts three popular options to the test
NCT ID NCT06907355
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed trial tested three common cough treatments—levodropropizine, a codeine combination, and ivy leaf extract—against a placebo in 196 adults with acute cough from upper respiratory infections. Participants took the medicine three times a day for four days. The main goal was to see how much cough severity changed after 48 hours. The results could help guide which over-the-counter or prescription cough medicine is most effective.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Levodropropizine, Codeine (with Pseudoephedrine and Chlorphenamine), Ivy Leaf (Hedera Helix Extract)
- What this could lead to
- If this trial shows one treatment works better than the others, it could help doctors choose the most effective cough medicine for common colds.
- What could go wrong
- This is a completed Phase 4 trial with 196 participants, so results are already in. However, the findings may not apply to everyone, and any benefits might be small compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
196 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Have between 18 and 65 years of age. 2. Have an URTI with Jackson Score ≥6 points. 3. Have moderate or severe cough assessed by having a score ≥2 points in the cough domain of the Jackson Score and ≥60mm on the cough visual analogue scale (VAS). 4. Have initiated cough within 5 days of enrollment. 5. Be capable of understanding and complying with study procedures. 6. Sign a written informed consent. Exclusion Criteria: 1. Physician considers that potential participant needs or might need to use antibiotics at the screening visit (e.g., suspected bacterial otitis, bacterial tonsilitis, bacterial sinusitis, bacterial bronchitis, or bacterial pneumonia) or suspected need for antibiotics during patient follow-up. 2. Individuals with pre-existing respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), or any chronic lower respiratory tract disease. 3. Uncontrolled cardiovascular condition (hypertension, diabetes, etc.) 4. Contraindications to use Levodropropizine, Codeine, Pseudoephedrine, Chlorphenamine, or Ivy Leaf (Hedera Helix Extract), including Fructose Intolerance, Bronchorrhea, Kartagener Syndrome, Ciliary Dyskinesia, Respiratory Failure, Bronchial Obstructive Syndrome, severe Hypertension, Peptic Ulcer, using Monoamine Oxidase Inhibitors (MAOIs), CYP2D6 ultra-fast metabolizers. 5. Pregnancy, suspected pregnancy, desired pregnancy, or breastfeeding. 6. Contraindications to the study medications will also result in exclusion, including known or suspected allergies to Levodropropizine, Codeine, Pseudoephedrine, Chlorphenamine, or Hedera Helix Extract. 7. Known adverse reactions to Levodropropizine, Codeine, Pseudoephedrine, Chlorphenamine, or Hedera Helix Extract. 8. Participants currently using medications that could interfere with study outcomes, such as other cough suppressants, inhalers, or systemic corticosteroids. 9. Researcher considers participant might not comply with study procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Upper resp tract infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pontificia Universidad Catolica de Chile
Santiago, Chile
More trials for these conditions
Other studies related to the condition(s) this trial covers.